Why the study?
Does discontinuation of rosuvastatin and administration of IV fluids improve rosuvastatin-induced rhabdomyolysis in a post-PTCA patient?
Population
1 postpercutaneous transluminal coronary angioplasty patient
Design
Case report
Follow-up
10 th day
Authors
Loading...
Suggests reversibility of rosuvastatin rhabdomyolysis with discontinuation and IV fluids; hypothesis-generating for post-PTCA patients.
Does discontinuation of rosuvastatin and administration of IV fluids improve rosuvastatin-induced rhabdomyolysis in a post-PTCA patient?
High-dose rosuvastatin can cause life-threatening but reversible rhabdomyolysis, which improves upon drug discontinuation and IV fluid administration.
Pradhan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: